BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maccallini C, Ammazzalorso A, De Filippis B, Fantacuzzi M, Giampietro L, Amoroso R. HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer. Pharmaceuticals 2022;15:667. [DOI: 10.3390/ph15060667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sixto-López Y, Ordaz-Pichardo C, Gómez-Vidal JA, Rosales-Hernández MC, Correa-Basurto J. Cytotoxic evaluation of YSL-109 in a triple negative breast cancer cell line and toxicological evaluations. Naunyn Schmiedebergs Arch Pharmacol 2023. [PMID: 36694011 DOI: 10.1007/s00210-023-02396-7] [Reference Citation Analysis]
2 Reddy Manne M, Panicker RR, Ramakrishnan K, Hareendran HMK, Kumar Pal S, Kumar S, Pallepogu R, Desikan R, Sivaramakrishna A. Synthesis and Biological Evaluation of a Series of Quinoline‐Based Quinazolinones and Carbamic Anhydride Derivatives. ChemistrySelect 2023;8. [DOI: 10.1002/slct.202204508] [Reference Citation Analysis]
3 Ganai SA, Shah BA, Yatoo MA. Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer. Advances in Cancer Research 2023. [DOI: 10.1016/bs.acr.2022.12.003] [Reference Citation Analysis]
4 Taurelli Salimbeni B, Corvaja C, Valenza C, Zagami P, Curigliano G. The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. Expert Opin Investig Drugs 2022;31:1203-26. [PMID: 36413823 DOI: 10.1080/13543784.2022.2151433] [Reference Citation Analysis]